Stayble Therapeutics ABOSTO:STABL 28 Quick Ratio is 1.43 as of Mar. 2026, which is 77% below its 10-year median of 6.12. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Stayble Therapeutics AB ranks worse than 73.8% on this metric.
Stayble Therapeutics AB has a quick ratio of 1.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for Stayble Therapeutics AB's Quick Ratio or its related term are showing as below:
OSTO:STABL'
s Quick Ratio Range Over the Past 10 Years
Min: 0.2 Med: 6.12 Max: 63.53
Current: 1.43
During the past 10 years, Stayble Therapeutics AB's highest Quick Ratio was 63.53. The lowest was 0.20. And the median was 6.12.
OSTO:STABL's Quick Ratio is ranked worse than 73.8% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs OSTO:STABL: 1.43
Stayble Therapeutics AB (OSTO:STABL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Stayble Therapeutics AB Quick Ratio Related Terms
Stayble Therapeutics AB Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:STABL vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Stayble Therapeutics AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stayble Therapeutics AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Stayble Therapeutics AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Stayble Therapeutics AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stayble Therapeutics AB (OSTO:STABL) has a Quick Ratio of 1.43 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Stayble Therapeutics AB and its competitors. This is 77% below median its historical median of 6.12. Over the past decade, Stayble Therapeutics AB's Quick Ratio has ranged from 0.20 to 63.53. According to the industry distribution chart, Stayble Therapeutics AB ranks #1042 out of 1412 companies in the Biotechnology industry, placing it in the top 73.8%.
Is Stayble Therapeutics AB's Quick Ratio too high?
Stayble Therapeutics AB's current Quick Ratio of 1.43 is 77% below median its 10-year median of 6.12. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 63.53. The Biotechnology industry median Quick Ratio is 3.60. Stayble Therapeutics AB's value of 1.43 is 60.3% below this industry median. Based on the distribution chart, Stayble Therapeutics AB ranks #1042 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #1042 out of 1412 companies for Quick Ratio. This places Stayble Therapeutics AB in the lower half of its industry. The industry median Quick Ratio is 3.60. Stayble Therapeutics AB's value of 1.43 is 60.3% below this benchmark. Historically, Stayble Therapeutics AB's own Quick Ratio has ranged from 0.20 to 63.53 over the past decade. While the company's 10-year median is 6.12 vs. the industry median of 3.60, Stayble Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stayble Therapeutics AB's current Quick Ratio of 1.43 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Stayble Therapeutics AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stayble Therapeutics AB's current Quick Ratio is 1.43, which is 77% below median its own 10-year median of 6.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current Quick Ratio of 1.43. The current Quick Ratio is 1.43, which is 77% below median its 10-year median of 6.12 and 60.3% below the Biotechnology industry median of 3.60. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current Quick Ratio is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score
Get the complete analysis for OSTO:STABL
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STABL has been successfully added to your 
